Testing EH-301 and NAC with Riluzole for ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with ALS in the last 18 months
- Age 18 to 75 years
- ALS functional score of 30 or higher (means enough ability to do daily activities)
- Breathing capacity (FVC) at least 70% of normal
- Taking Riluzole for at least 30 days before starting the study
- No other major health issues like heart disease, cancer, or severe lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests a new way of giving riluzole, a medicine already used for ALS, by delivering it directly into the fluid around the spinal cord using a small pump. It aims to see if this method is safe and might work better for people with ALS.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This study tests whether the drug colchicine can help people with ALS. It aims to see if taking colchicine in addition to your usual riluzole treatment slows the progression of the disease.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.